Report
Adam Fleck
EUR 98.48 For Business Accounts Only

Transurban’s Quarterly Revenue Tracks Our Full-Year Forecasts; Securities Overvalued

Wide-moat Transurban’s March quarter traffic and revenue update puts the toll-road operator on track to meet our fiscal 2017 forecast, and we reiterate our AUD 10.50 fair value estimate per security. At the current market quote of AUD 12.00, the securities look slightly overvalued.
Transurban saw quarterly average daily traffic, or ADT, climb 5.3% from the previous corresponding period, or pcp, with toll rate increases and positive mix from larger vehicles driving 10.2% growth in proportional to...
Underlying
Transurban Group Ltd.

Transurban Group is engaged in the development, financing, operation and maintenance of toll road networks as well as management of the associated customer and client relationships. Co. manages and develops urban toll road networks in Australia and the U.S. Co. owns concession assets across four key market segments: Victoria, New South Wales, Queensland and the Greater Washington Area.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Adam Fleck

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch